Roche Holding AG (FRA:RHO5)

Germany · Delayed Price · Currency is EUR

356.25

-0.60 (-0.17%)

Inactive · Last trade price on Mar 16, 2026

Market Cap	284.35B +11.0%
Revenue (ttm)	68.05B +1.5%
Net Income	13.83B +55.6%
EPS	17.23 +55.6%
Shares Out	n/a
PE Ratio	20.55
Forward PE	15.87
Dividend	10.85 (3.06%)
Ex-Dividend Date	Mar 12, 2026

Volume	91
Open	358.95
Previous Close	356.85
Day's Range	353.05 - 358.95
52-Week Range	259.15 - 411.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 24, 2026

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]

Industry Pharmaceutical Preparations

Founded 1896

Employees 103,249

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol RHO5

Full Company Profile

Financial Performance

In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.

Financial numbers in CHF Financial Statements